• Single Cell Analysis Technologies

    A challenge associated with single cell omics methods is to capture quantitative, multiplex information from single cells, while retaining the tissue context of those cells. New programs in the Heath group are focused on addressing this challenge.

  • Protein Catalyzed Capture Agents (PCCs)

    We have developed the PCC approach as an all synthetic approach towards identifying selective, high affinity binders to specific epitopes of specific proteins. Current PCC programs involve the development of a high throughput PCC production approach, and the use of the PCC technology to develop drug candidates against challenging targets, such as mutated KRas, mutated SOD1, or the malaria target pf.HRP-2.

  • Cancer Immunotherapy

    We utilize single cell methods, coupled with large scale molecular dynamics calculations to develop a molecular-level understanding of patient responses to engineered T cell and drug-based cancer immunotherapies, and to engineer new therapies for the most challenging patients.

  • Predicting Cancer Therapy

    We are developing single cell proteomics and single cell metabolomics methods that, when combined with kinetic studies and statistical physics models, can yield effective cancer treatment strategies for individual patients, and can unveil mechanisms of drug response and resistance.